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Introduction
Up to one-third of patients with early stage breast cancer
will eventually die from the disease, and most of these
(~80%) will have bone metastases. Although a majority of
these bone metastases are destructive or osteolytic, a sig-
nificant percentage also causes abnormal bone formation
or osteosclerotic lesions. Once tumor has metastasized to
bone, the disease is incurable. Because the average sur-
vival of breast cancer patients following diagnosis of bone
metastases is 24–36 months, the morbidity of bone pain,
fracture, hypercalcemia and nerve compression syn-
dromes is longstanding. Therapeutics to treat and prevent
these devastating complications of bone metastases are
therefore in great demand.
Seed and soil hypothesis
It is well established that the skeleton is the most common
site of distant metastases of breast cancer cells. Paget pro-
posed, in 1889, that the affinity of certain cancers to metas-
tasize to bone was due to the fact that the bone provides a
‘fertile soil’ or environment for the cells to germinate [1]. This
seed and soil hypothesis is supported by the fact that bone
is a repository for a number of growth factors and that
osteoclastic bone resorption releases these growth factors.
Histological sections of breast cancer metastases to bone
reveal tumor cells adjacent to osteoclasts that are resorbing
bone. These observations, combined with the clinical data
demonstrating that bisphosphonate inhibitors of bone
resorption reduce skeletal morbidity in breast cancer
patients, indicate that bone destruction in breast cancer
osteolysis is mediated by the osteoclast.
Our laboratory and other laboratories have provided evi-
dence of a ‘vicious cycle’ involving breast cancer and
bone. In this vicious cycle, metastatic breast cancer cells
in bone produce factors (such as parathyroid hormone-
related protein) that stimulate osteoclastic bone resorp-
tion. This production results in the release of growth
factors, such as transforming growth factor-β, from the
bone matrix [2,3]. Growth factors, in turn, stimulate tumor
growth and production of more parathyroid hormone-
related protein, resulting in a ‘vicious cycle’ that further
fuels the bone destruction and tumor growth [2,3].
These local tumor–bone cell interactions resulting in oste-
olysis are the final steps of the journey that a tumor cell
navigates from the primary site to the skeleton. The tena-
cious tumor cell must undergo the multistep process of
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the metastatic cascade before it comfortably settles in
bone. Specifically, the tumor cell must detach from the
primary site, enter tumor vasculature to reach the circula-
tion, survive host immune response and physical forces in
the circulation, arrest in a distant capillary bed, escape the
capillary bed, and proliferate in the metastatic site.
The events involved in entering the tumor vasculature are
similar to those involved with exiting the vasculature in the
bone marrow cavity. These events include attachment of
tumor cells to the basement membrane, tumor cell secre-
tion of proteolytic enzymes to disrupt the basement mem-
brane, and migration of tumor cells through the basement
membrane. Attachment of tumor cells to basement mem-
branes and to other cells is mediated through cell adhe-
sion molecules such as laminin and E-cadherin. Tumor cell
secretion of substances such as metalloproteinases facili-
tates disruption of the basement membranes and
enhances invasion. Inherent tumor cell motility or motility in
response to chemotactic stimuli are also important factors
for tumor cell invasion to the secondary site.
A number of other tumor types frequently metastasize to
bone, including prostate, lung, thyroid, and renal cell car-
cinomata. Multiple myeloma is a primary hematologic
malignancy that causes osteoclast-mediated bone
destruction but is not a metastatic tumor per se.
However, many of the tumor cell–bone cell interactions
that cause the bone destruction are similar to those impli-
cated in breast cancer osteolysis. Although this review
focuses on breast cancer metastases to bone, the
studies reviewed here offer general mechanisms that can
be applied to other tumor types.
Bisphosphonates: what they are and what
they do
Bisphosphonates are synthetic analogs of inorganic
pyrophosphate. They are taken up preferentially by the
skeleton and are strongly bound to hydroxyapatite on the
surface of bone. Bisphosphonates are potent inhibitors of
osteoclastic bone resorption. The effects of these drugs
are primarily on the bone-resorbing osteoclasts but may
also target osteoblasts, macrophages and tumor cells
[4–8]. The mechanisms by which bisphosphonates inhibit
osteoclast activity, and the relative potencies with which
they do so, are dependent on the molecular structure of
each compound.
The major mechanism of the nitrogen-containing bisphos-
phonates to decrease osteoclast number, osteoclast activ-
ity and bone resorption is by induction of osteoclast
apoptosis [9]. As described by Fleisch in this issue [10],
bisphosphonates inhibit farnesyl diphosphate synthase in
the mevalonate pathway and thereby prevent protein preny-
lation of small GTPase signaling proteins required for
osteoclast function [11,12]. The degree to which nitrogen-
containing bisphosphonates inhibit bone resorption corre-
lates with the capacity to cause apoptosis in cells of the
osteoclast lineage, as well as with the capacity to inhibit
farnesyl diphosphate synthase and protein prenylation in
the osteoclast [11]. The non-nitrogen-containing bisphos-
phonates, such as clodronate, do not inhibit protein preny-
lation and have a different mode of action that may involve
the formation of cytotoxic metabolites in osteoclasts or inhi-
bition of protein tyrosine phosphatases [12].
Bisphosphonates also affect cells other than osteoclasts
in the bone microenvironment. Derenne et al. showed that
the bisphosphonates pamidronate and zoledronate inhib-
ited interleukin-6-induced production of matrix metallopro-
teinase-1 by bone marrow stromal cells [13]. In vitro
studies have also shown that nitrogen-containing bisphos-
phonates inhibit the adhesion of breast cancer cells to
bone and bone matrix [14].
Even more intriguing are those results indicating that bis-
phosphonates may have direct effects on the tumor cells
themselves, as reviewed in detail by Senaratne and
Colston in this issue [15]. Bisphosphonates have been
shown to decrease the proliferation and viability of human
tumor cells lines, as well as to increase the apoptotic
index of the human tumor cell lines [13,16]. Numerous
investigators have demonstrated that bisphosphonates
significantly reduce tumor invasion and adhesion to bone
[13,14,16–19].
Bisphosphonates in preclinical animal
models of breast cancer
Animal studies with bisphosphonates are essential to
understanding the effects of these compounds on both
bone and tumor cells in vivo. Four distinct models of oste-
olytic bone metastases (MDA-MB-231, 4T1, ENU-1564,
and Walker carcinosarcoma 256B) and one model of
osteoblastic metastases (MCF-7) in breast cancer have
been used to test the efficacy and dosing of bisphospho-
nates. Table 1 summarizes the effects of bisphosphonates
on the development and progression of bone metastases
in these models.
MDA-MB-231 experimental model
Yoneda et al. have utilized the human estrogen receptor-
alpha negative breast cancer cell line, MDA-MB-231, in a
nude mouse model of metastatic breast cancer to bone.
Mice develop osteolytic bone metastases 3–4 weeks post
tumor inoculation into the left cardiac ventricle [20]. Bone
metastases are a prominent feature of this model and
closely resemble the osteolytic metastases frequently
seen in breast cancer patients.
Risedronate blocked osteoclastic bone resorption in this
model, resulting in fewer new bone metastases and
delayed progression of existing metastases [21]. Histo-c
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.morphometric analysis of the bones showed a decrease in
tumor volume in the bone in mice treated with risedronate
[21]. Risedronate also increased the survival of the
animals compared with untreated mice [21]. Sasaki et al.
tested an experimental bisphosphonate, YH529, for the
ability to decrease bone metastases, and observed a
dose-dependent decrease in both osteolytic lesion
number and area when the drug was given in a preventa-
tive manner (from the time of tumor inoculation until the
end of the experiment) [22]. When YH529 was adminis-
tered to treat established bone metastases, however, it
had little effect [22].
Yoneda et al. also studied the effects of the bisphospho-
nate ibandronate on a subclone of MDA-MB-231 cells
that is reported to more reliably form metastases to the
skeleton and adrenal glands [23]. Ibandronate was admin-
istered in a ‘preventative’ protocol and a ‘therapeutic’ pro-
tocol. In groups treated according to the preventative
protocol, in which mice received daily injections of iban-
dronate beginning at the time of tumor inoculation and
continued for the duration of the experiment, a decrease in
osteolytic skeletal metastases was observed [23].
However, adrenal metastases were increased in mice
treated with ibandronate; an observation that is consistent
with the data of other studies [21–24]. In the therapeutic
protocol, mice received ibandronate daily only after the
development of osteolytic bone metastases. In this case,
ibandronate (unlike YH529 in earlier experiments)
decreased the progression of the established bone metas-
tases compared with the control group, with no effect on
adrenal metastases [23].
Hiraga et al. have more recently provided evidence that
ibandronate acts by reducing osteoclastic bone resorption
and by increasing the apoptosis of osteoclasts [25]. In
addition, ibandronate was shown to increase the apopto-
sis of tumor cells in the experimental bone metastasis
model but not in orthotopic mammary fat pad tumors, indi-
cating that the primary effect is in bone and tumors in
bone [25].
4T1 experimental model
The second model, also used by Yoneda and colleagues,
involves a mouse mammary tumor cell line, 4T1. This
model is clinically relevant because syngeneic, immuno-
competent mice are inoculated orthotopically into the
mammary fat pad, and metastases occur in bone and soft
tissue. This is one of the few models in which the cells
must go through the multiple steps of the metastatic
cascade to develop bone metastases. A primary tumor is
usually evident in these mice about 1 week post tumor
inoculation. Metastases are identified in the lungs and liver
around 2 weeks post tumor inoculation. By week 3 the
mice have distant metastases to the skeleton, the kidney,
the adrenal glands, the heart and the spleen, and they do
not usually survive beyond week 4 or 5 post tumor inocu-
lation. The pattern of metastases and the histologic
appearance are similar to those seen in human patients.
This model allows for the simultaneous study of the effects
of bisphosphonates on bone and soft tissue metastases.
This model was used to examine the therapeutic value of
zoledronate, the most potent of the approved bisphospho-
nates. Administration of the bisphosphonate was begun
as soon as the orthotopic tumor was apparent (approxi-
mately 7 days post tumor inoculation) [23]. Analysis of X-
rays of both the treated and the untreated mice revealed a
decrease in lesion area in the long bones of the mice
receiving zoledronate. In addition, zoledronate-treated
mice exhibited a decrease in osteolytic tumor lesion area
in the lumbar spine by histomorphometric analysis [26].
The compound prevented the marked bone destruction
seen in the trabecular bone of the tibial growth plates of
control mice [26]. Daily treatment of mice bearing 4T1
tumors with zoledronate increased both osteoclast and
tumor cell apoptosis within the bone metastases [26].
Finally, zoledronate also resulted in a decrease in the
lesion area by X-ray analysis of existing bone metastases
by 4T1 cells, while ibandronate and alendronate had no
effect on established bone metastases [26]. No effect
was observed on visceral metastases or on the primary
tumor, however, indicating that the actions of zoledronate
as used in this study are limited to bone.
The 4T1 bone metastases model has also been utilized to
look at combinations of bisphosphonates with anticancer
agents, a situation that more closely resembles the clinical
scenario. Yoneda et al. [23] examined the effects of
incadronate and zoledronate with the anticancer agent,
UTF. The combination therapy inhibited metastasis to
bone, the liver and the lung. UTF alone resulted in a
decrease in tumor burden in the mammary fat pad, as well
as in decreased metastases to the lung, the liver and the
skeleton [23]. The decrease in bone metastases by UTF
alone is probably due to the initial decrease in the size of
the primary tumor.
ENU-1564 experimental model
A third model used to study the effects of bisphospho-
nates is a rat model using the ENU1564 mammary adeno-
carcinoma cell line. Rats are administered the mammary
adenocarcinoma cells via intracardiac inoculation and are
monitored for tumor development and the subsequent
development of metastases.
This model was used to examine the effects of risedronate
on bone metastases. Consistent with the results observed
with the MDA-MB-231 model, risedronate resulted in a
reduction in the number of skeletal metastases and in the
size of the lesions in the skeleton [27]. No difference in
visceral metastases was observed [27].
Breast Cancer Research    Vol 4 No 1 Padalecki and GuiseWalker carcinosarcoma 256B experimental model
The fourth model used to assess the use of bisphospho-
nates in the treatment of skeletal metastases secondary to
breast cancer is the Walker carcinosarcoma 256B model.
This is a rat model of skeletal metastases in which the
cells are implanted directly into the bone. The growth of
the Walker carcinosarcoma 256B cells in bone also leads
to hypercalcemia, a common complication of bone metas-
tases. Krempien et al. [28] have also found that intra-aortic
administration of Walker carcinosarcoma 256B cells
results in both bone and adrenal metastases in rats. Pro-
phylactic treatment with clodronate, both short-term
(5-day treatment) and long-term (21-day treatment), inhib-
ited osteolysis is this model [28]. However, Krempien and
Manegold also found that the longer the treatment-free
intervals after short-term therapy, the less effective the
inhibition [29]. The Walker carcinosarcoma 256B models
have also been used to examine the effect of pamidronate
on skeletal metastases [24,30]. Krempien et al. reported a
reduction in skeletal metastases in rats treated with
pamidronate [30]. Surprisingly, a second group reported
that the tumor burden in bone increased following treat-
ment with pamidronate [30]. The latter result, however, is
not consistent with the clinical data that pamidronate
reduced skeletal complications in patients with multiple
myeloma and breast cancer [31–33].
Kurth et al. more recently examined the effects of daily
treatment with ibandronate on the bone quality of rats
inoculated with Walker carcinosarcoma 256B cells [34].
Treatment with ibandronate was shown to increase the
bone density and the bone stability compared with con-
trols [34].
Bisphosphonates and osteoblastic bone metastases
The estrogen receptor positive human breast cancer cell
line, MCF-7, has been shown to produce osteoblastic or
mixed osteolytic and osteoblastic bone lesions following
intracardiac inoculation in a nude mouse model. It has
long been hypothesized that bone resorption precedes
the new bone formation of osteoblastic metastases, since
biochemical markers of osteoclastic bone resorption are
markedly increased in patients with osteoblastic meta-
stases. Yoneda et al. tested the hypothesis that blocking
bone resorption with bisphosphonates may affect the
ability of MCF-7 cells to cause osteoblastic metastases
[23]. Using the MCF-7 model, they looked at the effects of
both early (prior to tumor inoculation) and late (post tumor
inoculation, osteoblastic metastases established) treat-
ment with ibandronate [23]. Only the early treatment with
ibandronate resulted in inhibition of osteoblastic meta-
stases. This supports the hypothesis that a bone resorp-
tive phase precedes the development of osteoblastic
metastases. The use of bisphosphonates to inhibit this
resorptive phase may thus significantly reduce the
development of osteoblastic metastases.
Discussion
Studies of bisphosphonates in preclinical models of
breast cancer metastases to bone illustrate the impor-
tance of the bone microenvironment and osteoclastic
bone resorption in the development of skeletal metastases
of both osteolytic and osteoblastic nature. We have
learned from these studies that the primary action of bis-
phosphonates is on the bone resorbing osteoclasts, and
that bisphosphonates may exert secondary effects on the
tumor cells in bone. Zoledronate, the newest and most
potent bisphosphonate, showed promise in the preserva-
tion of bone in the 4T1 model of breast cancer metastasis
to bone [23]. It caused a decrease in the osteoclast
number and a decrease in the tumor burden in bone [23].
There are multiple explanations for this decrease in tumor
burden in bone. First, and most probable, the decrease in
osteoclastic bone resorption makes the skeleton a less
hospitable environment for the tumor cells, by reducing
the release of bone-derived growth factors that may stimu-
late tumor growth or production of osteolytic factors.
Second, the bisphosphonates may have a direct effect on
the tumor cells to induce apoptosis. While there are data
in vitro and in animal models to support this, the concen-
trations of bisphosphonates at which this occurs in vitro
are quite high. It is unclear whether such concentrations
occur in vivo. Such data have yet to be demonstrated in
humans with bone metastases. Finally, it is also possible
that the decrease in tumor burden in bone is due to an
effect of bisphosphonates on angiogenesis [35]. This
potential anti-angiogenic effect on tumors remains to be
investigated.
The observation in some of the animal models reported
here that clearly needs to be clarified in human studies is
the issue of extraskeletal metastases. That is, soft tissue
metastases were increased following treatment with bis-
phosphonates, an observation indicating that if the tumor
cells find the bone microenvironment inhospitable then
they may seed to other tissues. However, clinical data with
regard to this are inconsistent. Diel et al. found a decrease
in visceral metastases in patients with breast cancer fol-
lowing treatment with clodronate [36], while Saarto et al.
found an increase in visceral metastases [37].
Many questions remain regarding the use of bisphospho-
nates in the treatment of metastatic breast disease to the
skeleton. More work is needed to determine whether bis-
phosphonates truly have antitumor activity in humans, or
whether the reduction in tumor burden in bone is due to
the reduction of bone-derived growth factors released into
the local microenvironment as a consequence of inhibiting
osteoclastic bone resorption. Second, bisphosphonate
use in osteoblastic metastases needs to be further
explored to prove definitively that treatment inhibiting bone
resorption does indeed reduce osteoblastic disease. In
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eaddition, it still remains to be determined whether bisphos-
phonates increase survival in clinically relevant situations.
Patients with metastatic breast cancer are treated with
anticancer agents in addition to bisphosphonates, and
studies in animal models that mimic this situation would
provide more realistic evidence with regard to survival.
Finally, the use of bisphosphonates in the treatment of
bone metastases of other primary tumors is an area that
needs to be explored in both animal models and humans.
Many of these questions are currently under investigation,
and the answers should provide a strong rationale for the
use of bisphosphonates in cancer-induced morbidity of
the skeleton.
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